Wang J, Wang X, Zhuo E, Chen B, Chan S
Mol Med Rep. 2024; 31(1).
PMID: 39450549
PMC: 11541166.
DOI: 10.3892/mmr.2024.13375.
Pessino G, Scotti C, Maggi M, Immuno-Hub Consortium
Cancers (Basel). 2024; 16(5).
PMID: 38473265
PMC: 10931414.
DOI: 10.3390/cancers16050901.
Seo H, Chung W, Kwon Y, Kim S, Hong Y, Park W
Chem Rev. 2023; 123(19):11488-11558.
PMID: 37748126
PMC: 10571045.
DOI: 10.1021/acs.chemrev.3c00290.
Schwertheim S, Alhardan M, Manka P, Sowa J, Canbay A, Schmidt H
J Pers Med. 2023; 13(7).
PMID: 37511764
PMC: 10381647.
DOI: 10.3390/jpm13071152.
Abenavoli L, Scarlata G, Paravati M, Boccuto L, Luzza F, Scarpellini E
Biomedicines. 2023; 11(7).
PMID: 37509432
PMC: 10376769.
DOI: 10.3390/biomedicines11071792.
Downregulation of SOCS1 increases interferon-induced ISGylation during differentiation of induced-pluripotent stem cells to hepatocytes.
Edwards J, Delabat S, Badilla A, DiCaprio R, Hyun J, Burgess R
JHEP Rep. 2022; 4(12):100592.
PMID: 36439639
PMC: 9685392.
DOI: 10.1016/j.jhepr.2022.100592.
Pharmacological effects of Chinese medicine modulating NLRP3 inflammasomes in fatty liver treatment.
Liu T, Xu G, Liang L, Xiao X, Zhao Y, Bai Z
Front Pharmacol. 2022; 13:967594.
PMID: 36160411
PMC: 9492967.
DOI: 10.3389/fphar.2022.967594.
Toll-Like Receptor 4 Signaling in the Trabecular Meshwork.
Mzyk P, Hernandez H, Le T, Ramirez J, McDowell C
Front Cell Dev Biol. 2022; 10:936115.
PMID: 35912101
PMC: 9335276.
DOI: 10.3389/fcell.2022.936115.
The gut-liver axis in sepsis: interaction mechanisms and therapeutic potential.
Zhang X, Liu H, Hashimoto K, Yuan S, Zhang J
Crit Care. 2022; 26(1):213.
PMID: 35831877
PMC: 9277879.
DOI: 10.1186/s13054-022-04090-1.
Innate immune surveillance of the circulation: A review on the removal of circulating virions from the bloodstream.
Ander S, Li F, Carpentier K, Morrison T
PLoS Pathog. 2022; 18(5):e1010474.
PMID: 35511797
PMC: 9070959.
DOI: 10.1371/journal.ppat.1010474.
MD2 deficiency prevents high-fat diet-induced AMPK suppression and lipid accumulation through regulating TBK1 in non-alcoholic fatty liver disease.
Luo W, Ye L, Hu X, Wang M, Wang M, Jin L
Clin Transl Med. 2022; 12(3):e777.
PMID: 35343085
PMC: 8958353.
DOI: 10.1002/ctm2.777.
Endotoxins and Non-Alcoholic Fatty Liver Disease.
Kessoku T, Kobayashi T, Imajo K, Tanaka K, Yamamoto A, Takahashi K
Front Endocrinol (Lausanne). 2021; 12:770986.
PMID: 34777261
PMC: 8586459.
DOI: 10.3389/fendo.2021.770986.
The Gut Microbiota-Derived Immune Response in Chronic Liver Disease.
Won S, Park E, Jeong J, Ganesan R, Gupta H, Gebru Y
Int J Mol Sci. 2021; 22(15).
PMID: 34361075
PMC: 8347749.
DOI: 10.3390/ijms22158309.
The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target.
Kessoku T, Kobayashi T, Tanaka K, Yamamoto A, Takahashi K, Iwaki M
Int J Mol Sci. 2021; 22(15).
PMID: 34360923
PMC: 8347478.
DOI: 10.3390/ijms22158161.
Hepatic NOD2 promotes hepatocarcinogenesis via a RIP2-mediated proinflammatory response and a novel nuclear autophagy-mediated DNA damage mechanism.
Zhou Y, Hu L, Tang W, Li D, Ma L, Liu H
J Hematol Oncol. 2021; 14(1):9.
PMID: 33413510
PMC: 7791875.
DOI: 10.1186/s13045-020-01028-4.
3D-Hepatocyte Culture Applied to Parasitology: Immune Activation of Canine Hepatic Spheroids Exposed to .
Rodrigues A, Alexandre-Pires G, Valerio-Bolas A, Santos-Mateus D, Rafael-Fernandes M, Pereira M
Biomedicines. 2020; 8(12).
PMID: 33352885
PMC: 7766187.
DOI: 10.3390/biomedicines8120628.
Neutrophils interact with cholangiocytes to cause cholestatic changes in alcoholic hepatitis.
Takeuchi M, Vidigal P, Guerra M, Hundt M, Robert M, Olave-Martinez M
Gut. 2020; 70(2):342-356.
PMID: 33214166
PMC: 7906004.
DOI: 10.1136/gutjnl-2020-322540.
Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response.
Keenan B, Fong L, Kelley R
J Immunother Cancer. 2019; 7(1):267.
PMID: 31627733
PMC: 6798343.
DOI: 10.1186/s40425-019-0749-z.
Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases.
Fabris L, Fiorotto R, Spirli C, Cadamuro M, Mariotti V, Perugorria M
Nat Rev Gastroenterol Hepatol. 2019; 16(8):497-511.
PMID: 31165788
PMC: 6661007.
DOI: 10.1038/s41575-019-0156-4.
Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota.
Fiorotto R, Strazzabosco M
Cell Mol Gastroenterol Hepatol. 2019; 8(2):197-207.
PMID: 31075352
PMC: 6664222.
DOI: 10.1016/j.jcmgh.2019.04.013.